GlassScriptPhysician profile
Ranjan Bhayana
NPI 1366407173
$25,846.47
in general payments reported to CMS, 2019-2025
39 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $10K · 2021: $8,983 · 2022: $1,320 · 2023: $1,272 · 2024: $1,569 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,347.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $9,648.66 | 2020-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $4,416.09 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,756.03 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,142.28 | 2019-2025 | |
| Boston Scientific Corporation | $702.13 | 2019-2025 | Watchman Access System, General - Therapies, Emblem Mri S-Icd |
| Amgen INC. | $641.07 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $585.78 | 2021-2025 | Verquvo, Capvaxive |
| Lilly USA, LLC | $579.95 | 2020-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $548.94 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $531.69 | 2020-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $454.41 | 2019-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $288.02 | 2019-2025 | |
| Amarin Pharma, INC. | $260.13 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $256.29 | 2019-2023 | |
| Novo Nordisk INC | $229.79 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $210.99 | 2024 | Impella |
| Scpharmaceuticals INC. | $161.89 | 2023-2025 | |
| Cvrx, INC. | $152.19 | 2023-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $109.22 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $107.07 | 2021-2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.89 | 2019-2024 | Lifevest |
| Recor Medical INC | $105.85 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Kiniksa Pharmaceuticals International, Plc | $98.72 | 2024 | Arcalyst |
| Lundbeck LLC | $98.21 | 2019 | |
| Abbott Laboratories | $87.56 | 2019-2025 | Mitraclip, Amplatzer Amulet |
| Lexicon Pharmaceuticals, INC. | $87.32 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $79.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $61.52 | 2023-2024 | Evkeeza |
| Glaxosmithkline, LLC. | $48.99 | 2025 | Shingrix |
| Inspire Medical Systems, INC. | $43.16 | 2023 | Inspire |
| Bridgebio Pharma, INC. | $42.16 | 2025 | Attruby |
| Biotronik INC. | $33.19 | 2019 | |
| Abbvie INC. | $32.96 | 2025 | |
| Impulse Dynamics (USA) INC. | $32.78 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $28.81 | 2023 | Arcalyst |
| Heartflow, INC. | $25.51 | 2024 | |
| Sumitomo Pharma America, INC. | $21.29 | 2025 | Gemtesa |
| Seqirus USA INC | $19.05 | 2025 | Fluad, Flucelvax |
| Grifols USA, LLC | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjan Bhayana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.